These experiments show that O-GlcNAcylation of STAT5 can be detected in human hematopoietic cancer cell lines and the T92A mutation causes strongly decreased O-GlcNAcylation at T92, the major glycosylation site. The gene discussed is STAT5A; the disease is hematopoietic and lymphoid cell neoplasm.